OncoMatch/Clinical Trials/NCT06904313
Ultralow Dose PET Imaging for PSMA Expression
Is NCT06904313 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Piflufolastat F18 for healthy volunteer.
Treatment: Piflufolastat F18 — The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: psma-targeted therapy (lutetium-177)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Nuclear Imaging Institute · Englewood, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify